

**This communication should be viewed by:**  
 Primary Care Providers, Behavioral Health Providers, Clinical staff

## Pharmaceutical Policy Updates Effective April 1, 2026

To see current MVP Health Care® (MVP) Medical policies, sign in at [mvphealthcare.com](http://mvphealthcare.com), go to *Resources*, then *Medical Policies*. All policies are reviewed annually. This notice lists affected policies and their status, grouped into categories:

- **New** – Denotes a new policy
- **Updated** – Updated policies have content changes that may affect coverage criteria for services and/or drugs
- **Reviewed/No Changes**– Policies that have been reviewed but have no content change
- **Archived** – Denotes a policy that is no longer active

The policies outlined below will take effect on April 1, 2026, and will be accessible for review no later than March 1, 2026. Printed copies may be provided upon request.

Pharmaceutical Policy Name	Status
<b>Effective February 1, 2026</b>	
Casgevy	Updated
Eculizumab	Updated
Lyfgenia	Updated
Multiple Sclerosis Agents	Updated
MVP Cancer Guidance Program Oncology Medication Coverage and Review	Updated
MVP Cancer Guidance Program Oncology Medication Coverage and Review Part B	Updated
Weight Loss Medications	Updated
<b>Effective April 1, 2026</b>	
Acthar	Updated
Asfotase Alfa	Updated
Certolizumab	Updated
Certolizumab Part B	Updated
Donislecel	Reviewed/No Changes
Donislecel Part B	Reviewed/No Changes
GLP 1 Receptor Agonist PROSPECTIVE	Reviewed/No Changes
Infertility Drug Therapy (Commercial/Marketplace)	Reviewed/No Changes
Jynarque	Updated
Mail Order	Reviewed/No Changes
Male Hypogonadism	Updated
Male Hypogonadism Part B	Updated
Metformin ER	Reviewed/No Changes
Phenylketonuria Agents	Updated
Physician Prescription Eligibility	Reviewed/No Changes
Prescribers Treating Self or Family Members	Reviewed/No Changes
Tepezza	Reviewed/No Changes
Tepezza Part B	Reviewed/No Changes
Teplizumab	Reviewed/No Changes
Teplizumab Part B	Reviewed/No Changes
Tocilizumab	Updated
Tocilizumab Part B	Updated
Transgender Hormone Therapy (Medicaid/HARP)	Reviewed/No Changes
Yorviphath	Reviewed/No Changes